• Principal Investigator
  • Female

Dr. M.D. Hazenberg MD PhD

Position: Associate professor (UHD)
Main activities: Patient care, Research
Specialisation: Allogeneic hematopoietic stem cell transplantation; clinical care and research
foto M.D. Hazenberg is one of the AMC Principal Investigators
Focus of research:

Allogeneic hematopoietic stem cell transplantation and tumor immunology

AMC themes: Infection & Immunity, Oncology
Departments: Cell Biology and Histology, Experimental Immunology, Internal Medicine: Clinical Haematology
Gillissen MA, de Jong G, Kedde M, Yasuda E, Levie SE, Moiset G, Hensbergen PJ, Bakker AQ, Wagner K, Villaudy J, van Helden PM, Spits H, Hazenberg MD, Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. BLOOD ADV 2017;1 (19):1551-1564
Gillissen MA, Kedde M, de Jong G, Moiset G, Yasuda E, Levie SE, Bakker AQ, Claassen YB, Wagner K, Böhne M, Hensbergen PJ, Speijer D, van Helden PM, Beaumont T, Spits H, Hazenberg MD, AML-specific cytotoxic antibodies in patients with durable graft versus leukemia responses. BLOOD 2017;ahead of print [PubMed]
Vlijm-Kievit A, Jorna NGE, Moll E, Pajkrt E, Pals ST, Middeldorp S, Biemond BJ, Zeerleder SS, Tio MA, Kemper EM, Hazenberg MD, Acute lymphoblastic leukemia during the third trimester of pregnancy. LEUKEMIA LYMPHOMA 2017;ahead of print [PubMed]
Willemse SB, Bezuur DL, Blom P, Kneppers E, Verheij J, Zaaijer HL, Hazenberg MD, Hepatitis E virus infection and hepatic GvHD in allogeneic hematopoietic stem cell transplantation recipients. BONE MARROW TRANSPL 2017;52 (4):622-624 [PubMed]
de Weerdt I, van Hoeven V, Munneke JM, Endstra S, Hofland T, Hazenberg MD, Kater AP, Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia. HAEMATOLOGICA 2016;101 (11):E461-E464 [PubMed]
Drylewicz J, Vrisekoop N, Mugwagwa T, de Boer AB, Otto SA, Hazenberg MD, Tesselaar K, de Boer RJ, Borghans JAM, Reconciling Longitudinal Naive T-Cell and TREC Dynamics during HIV-1 Infection. PLOS ONE 2016;11 (3):e0152513 [PubMed]
Gillissen MA, de Jong G, Levie SE, Yasuda E, Bakker AQ, Evers LM, Pals ST, Huisman C, van Helden PM, Spits H, Hazenberg MD, AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses. BONE MARROW TRANSPL 2016;51 (9):1245-1248 [PubMed]
Gillissen MA, Yasuda E, de Jong G, Levie SE, Go D, Spits H, van Helden PM, Hazenberg MD, The modified FACS calcein AM retention assay: A high throughput flow cytometer based method to measure cytotoxicity. J IMMUNOL METHODS 2016;434:16-23 [PubMed]
Heijink DM, Kater AP , Hazenberg MD, Hagenbeek A, Kersten MJ, T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy. NETH J MED 2016;74 (4):147-151 [PubMed]
Munneke JM. Innate lymphoid cells in inflammation and repair. S.l.: s.n.; 2016. 184p. ISBN 978-94-028-0188-0 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Spits H, van Oers MHJ; copromotor(s): Hazenberg MD)
Munneke JM, Spruit MJA, Cornelissen AS, van Hoeven V, Voermans C, Hazenberg MD, The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature. TRANSPLANTATION 2016;100 (11):2309-2314 [PubMed]
Bernink JH, Krabbendam L, Germar K, de Jong E, Gronke K, Kofoed-Nielsen M, Munneke JM, Hazenberg MD, Villaudy J, Buskens CJ, Bemelman WA, Diefenbach A, Blom B, Spits H, Interleukin-12 and -23 Control Plasticity of CD127(+) Group 1 and Group 3 Innate Lymphoid Cells in the Intestinal Lamina Propria. IMMUNITY 2015;43 (1):146-160 [PubMed]
Ladell K, Hazenberg MD, Fitch M, Emson C, McEvoy-Hein Asgarian BK, Mold JE, Miller C, Busch R, Price DA, Hellerstein MK, McCune JM, Continuous Antigenic Stimulation of DO11.10 TCR Transgenic Mice in the Presence or Absence of IL-1 beta: Possible Implications for Mechanisms of T Cell Depletion in HIV Disease. J IMMUNOL 2015;195 (9):4096-4105 [PubMed]
Munneke JM, Hazenberg MD, Aangeboren lymfoïde cellen: innate lymphoid cells (ILCs). NED TIJDSCHR HEMATOL 2015;12:166-172
Haverman TM, Raber-Durlacher JE, Rademacher WMH, Vokurka S, Epstein JB, Huisman C, Hazenberg MD, de Soet JJ, de Lange J, Rozema FR, Oral complications in hematopoietic stem cell recipients: the role of inflammation. MEDIAT INFLAMM 2014;2014:378281 [PubMed]
Hazenberg MD, Spits H, Human innate lymphoid cells. BLOOD 2014;124 (5):700-709 [PubMed]
Munneke JM, Björklund AT, Mjösberg JM, Garming-Legert K, Bernink JH, Blom B, Huisman C, van Oers MHJ, Spits H, Malmberg KJ, Hazenberg MD, Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. BLOOD 2014;124 (5):812-821 [PubMed]
Teunissen MBM, Munneke JM, Bernink JH, Spuls PI, Res PCM, te Velde A, Cheuk S, Brouwer MWD, Menting SP, Eidsmo L, Spits H, Hazenberg MD, Mjösberg J, Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients. J INVEST DERMATOL 2014;134 (9):2351-2360 [PubMed]
Gentek R, Munneke JM, Helbig C, Blom B, Hazenberg MD, Spits H, Amsen D, Modulation of signal strength switches Notch from an inducer of T cells to an inducer of ILC2. FRONT IMMUNOL 2013;4:UNSP 334 [PubMed]
Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JAM, Immune activation and collateral damage in AIDS pathogenesis. FRONT IMMUNOL 2013;4 (4):UNSP 298 [PubMed]
Choi G, Meijer SL, Hazenberg MD, Disseminated bread yeast fungaemia in a baker's wife with acute myeloid leukaemia. BRIT J HAEMATOL 2012;158 (3):298 [PubMed]
Kwakernaak AJ, Hazenberg MD, Roelofs JJ, van Noesel CJ, van Oers MH, van Tellingen A, T-lymfoblastair lymfoom zich presenterend als primair renaal lymfoom met acute nierinsufficiëntie. NED TIJDSCHR HEMATOL 2012;9:34
Hazenberg MD, Biemond BJ, Pals ST, Zumpolle CM, Schinkel CJ, Linthorst GE, Hoekstra JBL, Vos JMI, Clinical pathological conference: a non-Hodgkin's lymphoma patient with persistent anaemia after chemotherapy. NETH J MED 2011;69 (10):469-473 [PubMed]
Kuijpers TW, Ijspeert H, van Leeuwen EMM, Jansen MH, Hazenberg MD, Weijer KC, van Lier RAW, van der Burg M, Idiopathic CD4(+) T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. BLOOD 2011;117 (22):5892-5896 [PubMed]
Kwakernaak AJ, Hazenberg MD, Roelofs JJTH, van Noesel CJM, van Oers MHJ, van Tellingen A, Precursor T-lymphoblastic lymphoma presenting as primary renal lymphoma with acute renal failure. NDT PLUS 2011;4 (5):289-291 [PubMed]
Cherpanath TGV, Nieuwdorp M, Hazenberg MD, van Eeden S, van der Sluijs AF, Large nocturnal eyes causing gastrointestinal bleeding in asymptomatic multiple myeloma. CMV enterocolitis. NETH J MED 2010;68 (10):324-327 [PubMed]
Vrisekoop N, den Braber I, de Boer AB, Ruiter AFC, Ackermans MT, van der Crabben SN, Schrijver EHR, Spierenburg G, Sauerwein HP, Hazenberg MD, de Boer RJ, Miedema F, Borghans JAM, Tesselaar K, Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. P NATL ACAD SCI USA 2008;105 (16):6115-6120 [PubMed]
Borghans JA, Bredius RG, Hazenberg MD, Roelofs H, Jol-van der Zijde EC, Heidt J, Otto SA, Kuijpers TW, Fibbe WE, Vossen JM, Miedema F, van Tol MJ, Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. BLOOD 2006;108 (2):763-769 [PubMed]
Ribeiro RM, Hazenberg MD, Perelson AS, Davenport MP, Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J VIROL 2006;80 (2):802-809 [PubMed]
Borghans JAM, Hazenberg MD, Miedema F, Limited role for the thymus in SIV pathogenesis. EUR J IMMUNOL 2005;35 (1):42-45 [PubMed]
Harris JM, Hazenberg MD, Poulin JF, Higuera-Alhino D, Schmidt D, Gotway M, McCune JM, Multiparameter evaluation of human thymic function: interpretations and caveats. CLIN IMMUNOL 2005;115 (2):138-146 [PubMed]
Koning FA, Otto SA, Hazenberg MD, Dekker L, Prins M, Miedema F, Schuitemaker H, Low-level CD4(+) T cell activation is associated with low susceptibility to HIV-1 infection. J IMMUNOL 2005;175 (9):6117-6122 [PubMed]
Hazenberg MD, Otto SA, van Rossum AMC, Scherpbier HJ, de Groot R, Kuijpers TW, Lange JMA, Hamann D, de Boer RJ, Borghans JAM, Miedema F, Establishment of the CD4(+) T-cell pool in healthy children and untreated children infected with HIV-1. BLOOD 2004;104 (12):3513-3519 [PubMed]
van Asten L, Danisman F, Otto SA, Borghans JAM, Hazenberg MD, Coutinho RA, Prins M, Miedema F, Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS 2004;18 (14):1885-1893 [PubMed]
Hazenberg MD, Borghans JAM, de Boer RJ, Miedema F, Thymic output: a bad TREC record. NAT IMMUNOL 2003;4 (2):97-99 [PubMed]
Hazenberg MD, Otto SA, Hamann D, Roos MTL, Schuitemaker H, de Boer RJ, Miedema F, Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation. AIDS 2003;17 (10):1419-1424 [PubMed]
Hazenberg MD, Otto SA, van Benthem BHB, Roos MTL, Coutinho RA, Lange JMA, Hamann D, Prins M, Miedema F, Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17 (13):1881-1888 [PubMed]
van Rij RP, Hazenberg MD, van Benthem BHB, Otto SA, Prins M, Miedema F, Schuitemaker H, Early viral load and CD4(+) T cell count, but not percentage of CCR5(+) or CXCR4(+) CD4(+) T cells, are associated with R5-to-X4 HIV type 1 virus evolution. AIDS RES HUM RETROV 2003;19 (5):389-398 [PubMed]
Davenport MP, Zaunders JJ, Hazenberg MD, Schuitemaker H, van Rij RP, Cell turnover and cell tropism in HIV-1 infection. TRENDS MICROBIOL 2002;10 (6):275-278 [PubMed]
Hazenberg MD. T cell turnover and thymic function in HIV-1 infection. S.l.: s.n.; 2002. 207p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Miedema F; copromotor(s): Hamann D, de Boer RJ)
Hazenberg MD, T-cell turnover during HIV infection. AIDS READ 2002;12:S10-S13
Hazenberg MD, Otto SA, de Pauw ES, Roelofs H, Fibbe WE, Hamann D , Miedema F, T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events. BLOOD 2002;99 (9):3449-3453 [PubMed]
Hazenberg MD, Otto SA, Wit FWNM, Lange JMA, Hamann D, Miedema F, Discordant responses during antiretroviral therapy role of immune activation and T cell redistribution rather than true CD4 T cell loss. AIDS 2002;16 (9):1287-1289 [PubMed]
van der Vliet HJJ, von Blomberg BME, Hazenberg MD, Nishi N, Otto SA, van Benthem BH, Prins M, Claessen FA, van den Eertwegh AJM, Giaccone G, Miedema F, Scheper RJ, Pinedo HM, Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J IMMUNOL 2002;168 (3):1490-1495 [PubMed]
Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen JJ, T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J MOL MED-JMM 2001;79 (11):631-640 [PubMed]
Hazenberg MD, Hamann D, Schuitemaker H, Miedema F, T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. NAT IMMUNOL 2000;1 (4):285-289 [PubMed]
Hazenberg MD, Otto SA, Cohen Stuart JW, Verschuren MC, Borleffs JC, Boucher CA, Coutinho RA, Lange JM, Rinke de Wit TF, Tsegaye A, van Dongen JJ, Hamann D, de Boer RJ, Miedema F, Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. NAT MED 2000;6 (9):1036-1042 [PubMed]
Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, Miedema F, Hamann D, T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). BLOOD 2000;95 (1):249-255 [PubMed]
Key publications

Munneke JM, Björklund AT, Mjösberg JM, Garming-Legert K, Bernink JH, Blom B, Huisman C, van Oers MHJ, Spits H, Malmberg KJ, Hazenberg MD, Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. BLOOD 2014;124 (5):812-821 [PubMed]
Hazenberg MD, Spits H, Human innate lymphoid cells. BLOOD 2014;124 (5):700-709 [PubMed]
Gillissen MA, de Jong G, Levie SE, Yasuda E, Bakker AQ, Evers LM, Pals ST, Huisman C, van Helden PM, Spits H, Hazenberg MD, AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses. BONE MARROW TRANSPL 2016;51 (9):1245-1248 [PubMed]
Munneke JM, Spruit MJA, Cornelissen AS, van Hoeven V, Voermans C, Hazenberg MD, The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature. TRANSPLANTATION 2016;100 (11):2309-2314 [PubMed]
Willemse SB, Bezuur DL, Blom P, Kneppers E, Verheij J, Zaaijer HL, Hazenberg MD, Hepatitis E virus infection and hepatic GvHD in allogeneic hematopoietic stem cell transplantation recipients. BONE MARROW TRANSPL 2017;52 (4):622-624 [PubMed]


All Publications

Research programmes

Innate and adaptive immunity following allogeneic hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation is an important therapeutic tool to cure patients with hematological malignancies because of the potent graft versus tumor (leukemia, lymphoma) effect it induces. HSCT is however frequently complicated by GvHD (about 70% of patients) and opportunistic infections. These complications are the cause of the typical high HSCT-associated morbidity, profoundly affecting the quality of life of HSCT recipients, and accounting for the high transplantation-related mortality - up to 30% - that characterizes allogeneic HSCT.

Research in my group focuses on the role of B lymphocytes in the induction of GvHD and GvL reactivity and has led to the highly exciting and paradigm-shifting finding that patients with strong anti-leukemic activity generate AML-specific B cells that produce leukemic blasts killing antibodies. A second line of research involves reconstitution and function of innate lymphoid cells (ILC), in particular the protective effect of ILC after allogeneic HSCT. A third line of research concerns T and B cell recovery dynamics during lymphocyte reconstitution following HSCT, as measured by in vivo labeling of dividing cells by deuterium.

 

Funding: NWO Clinical Fellowship, NWO VIDI/Aspasia, LSBR Fellowship, KWF

 

Faculty
Dr. M.D. Hazenberg MD PhD
Dr. B. Blom

Postdocs
Dr. V. Van Hoeven PhD
Dr. G. Moiset PhD
Dr. M.M. Shikhagaie

PhD Students
Drs. M.A. Gillissen MD
Drs. G. de Jong MD (AIMM Therapeutics)
Y.F. van Lier
S.Z. Omar

Others
N. Haverkate MSc

Prof. dr. M.H.J. van Oers (Pathogenesis and Immunotherapy of B cell malignancies)

Other research related activities
  • Contribution to guidelines and protocols, HOVON werkgroep Stamceltransplantatie
Current research funding
  • AMC (Vrijgesteld)
  • KWF Kankerbestrijding
  • Landsteiner Stichting voor Bloedtransfusie Research
  • Stichting AMC Foundation (Vrijgesteld)
  • ZonMw